Introduction:We evaluated the safety and obstetric outcomes of patients with abnormal placental implantation who underwent prophylactic Caesarean iliac balloon insertion. Methods: Clinical and procedural records of patients with abnormal placental implantation (i.e., high-grade placenta praevia and/or placenta accreta) undergoing prophylactic Caesarean iliac artery balloon insertion in a tertiary referral hospital from September 2009 to April 2016 were reviewed. Patients' demographics, procedural complications (e.g., dissection and thromboembolism) and outcomes (estimated blood loss, transfusion requirements, immediate/delayed hysterectomy rate, postoperative sepsis, and immediate maternal/fetal mortality) were analysed. Results: Twenty-three cases were included in the study. The median age of the patients was 36 years (range, 28-47 years). A total of 91.3% (21/23) were high-grade placenta praevia (34.8% grade III and 56.5% grade IV) with 69.6% (16/23) co-existing placenta accreta. All prophylactic iliac balloon insertion procedures were uneventful without major complications such as dissection or thromboembolic events. The median blood loss was 1700 mL (100-8000 mL). The mean units of packed cells, platelets, and fresh frozen plasma transfused were 2.5, 2.2, and 2.0, respectively. The immediate and delayed hysterectomy rates were 34.8% (8/23) and 13.0% (3/23), respectively. Postoperative sepsis incidence was 8.7% (2/23). No immediate maternal or fetal mortality was recorded. Overall, the obstetric outcomes were comparable to data published in the literature. Conclusion: Prophylactic Caesarean iliac artery balloon insertion for patients with abnormal placental implantation is feasible and safe. The obstetric outcomes were comparable to data published in the literature.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.